WEBULL
WebtradeDownload

Organo (TSE:6368) Stock Revenue Climbs While Profit Slips

Simply Wall St · 1d ago

Organo stock came into this quarter looking tired, with the price roughly flat over the past week and down over the past month, even as longer term returns stayed positive. The headline from these Q1 2027 results is a clear margin story. Net income of ¥3,436m on revenue of ¥42,183m points to profitability that still supports a trailing P/E of 23.5x, sitting between pricier peers and a cheaper machinery sector. Short term growth has cooled, yet multi year earnings and margin trends still anchor the longer term case investors will be weighing after this release.

Is Organo fairly priced for this mix of strong multi year earnings growth and a P/E that sits between peers and the wider machinery sector, or is the stock carrying hidden expectations? See how the current multiples compare with cash flows and profitability trends in the full valuation analysis for Organo

Q1 2027 Earnings Summary

  • Revenue (Q1 2027 vs. Q1 2026): ¥42,183m vs. ¥38,110m (up about 10.7%)
  • Net Income (Q1 2027 vs. Q1 2026): ¥3,436m vs. ¥3,642m (down about 5.7%)
  • Basic EPS (Q1 2027 vs. Q1 2026): ¥74.72 vs. ¥79.23 (down about 5.7%)
  • Net Margin (TTM Q1 2027 vs. TTM Q1 2026): 15.5% vs. 14.8% (modest margin improvement)

Prefer clean charts instead of another wall of quarterly numbers and ratios? View Organo's full picture, including a clear valuation breakdown in an easy visual format, in the company report for Organo.

TSE:6368 Trailing 12-Month Revenue & Expenses Breakdown as at Aug 2026
TSE:6368 Trailing 12-Month Revenue & Expenses Breakdown as at Aug 2026

Organo bullish signals in water infrastructure demand

For investors leaning positive on Organo, the latest quarter still gives some support. Revenue moved to ¥42,183m from ¥38,110m, which fits a story of steady demand for water treatment and ultrapure systems across industrial customers. Net margin on a trailing basis improved from 14.8% to 15.5%. That suggests the core engineering and chemicals mix is not being priced away in competitive bids and that the business can still translate project activity into healthy profitability.

Organo downside risks in earnings quality

The weaker side of the Organo story shows up in earnings. Net income slipped from ¥3,642m to ¥3,436m and basic EPS followed the same pattern. That means stronger top line did not translate into higher profit in the period. For a project driven industrial stock, this can feed concerns about cost inflation, mix, or project timing. The margin improvement on a trailing basis helps, but the near term profit dip keeps alive questions about how consistent earnings can be through the cycle.

Compare Organo's margin resilience and recent profit softness with what institutional analysts are expecting next. See the consensus price target analysis for Organo to check how current targets stack up against the latest Q1 2027 results and the ¥14,415 share price as of 4 August 2026.

Stay Ahead With Organo And Simply Wall St

If Organo's mix of steady revenue and softer recent earnings has you watching for a better entry point, register for free with Simply Wall St and add it to a Watchlist to track the share price against fair value and key fundamentals. Once you own the stock, use the Portfolio Command Center to cut through day to day noise and focus on the most important updates to Organo and your wider holdings. Round this out by tapping into the Community to see how other investors are thinking about the same risks and opportunities. This way you can spot potential catalysts and warning signs early and stay a step ahead of the market.

Seeking Fresh Alternatives Beyond Organo

Some stocks are already building breakout momentum while others are dropping under the radar for now. Spot the fresh ideas before the crowd and act now.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.